GSK.L · LSE · Healthcare
GSK plc
Also onConsensus Drift
Implied value per share
GBp 3756.15
Market price
GBp 1877.50
Implied upside
+100.1%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (GBP). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | GBP 33.9bn | GBP 35.1bn | GBP 36.4bn | GBP 37.7bn | GBP 39.1bn | +3.7% |
| EBIT | GBP 7.6bn | GBP 7.9bn | GBP 8.2bn | GBP 8.5bn | GBP 8.8bn | +3.7% |
| NOPAT | GBP 6.6bn | GBP 6.8bn | GBP 7.1bn | GBP 7.3bn | GBP 7.6bn | +3.7% |
| Add depreciation & amortisation | GBP 2.5bn | GBP 2.6bn | GBP 2.7bn | GBP 2.8bn | GBP 2.9bn | +3.7% |
| Less capital expenditure | GBP -2.9bn | GBP -3.0bn | GBP -3.1bn | GBP -3.2bn | GBP -3.3bn | +3.7% |
| Less increase in working capital | GBP -434.0m | GBP -449.9m | GBP -466.3m | GBP -483.4m | GBP -501.1m | +3.7% |
| Free cashflow to firm | GBP 5.8bn | GBP 6.0bn | GBP 6.3bn | GBP 6.5bn | GBP 6.7bn | +3.7% |
| Discount factor | 0.9680 | 0.9071 | 0.8500 | 0.7965 | 0.7464 | - |
| Present value | GBP 5.6bn | GBP 5.5bn | GBP 5.3bn | GBP 5.2bn | GBP 5.0bn | -2.9% |
| Present Value Of The Forecast | GBP 26.6bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.50% | GBP assumption - no free live source available for this market (assumption) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.524 | Reported 0.290, pulled toward 1.0 (Blume) |
| Cost of equity | 7.38% | Risk-free + beta x equity risk premium |
| Cost of debt | 4.50% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | GBP 75.2bn | 80.9% of capital |
| Total debt | GBP 17.7bn | 19.1% of capital, book value as a proxy |
| Tax rate | 13.8% | Effective, capped at statutory |
| WACC | 6.72% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
84% of EV
- Forecast FCFF, final year
- GBP 6.7bn
- Capex at depreciation, working capital in reinvestment
- GBP 9.0bn
- Less reinvestment at g/ROIC (12.5% of NOPAT)
- GBP -1.1bn
- Capitalised
- GBP 7.9bn
- ROIC (reported)
- 20.0%
- Terminal value, undiscounted
- GBP 191.0bn
- Terminal value, discounted
- GBP 142.6bn
- Enterprise value
- GBP 169.2bn
- Less net debt
- GBP 14.6bn
- Equity value
- GBP 154.6bn
Exit at 8.4x EBITDA
74% of EV
- Terminal value, undiscounted
- GBP 99.2bn
- Terminal value, discounted
- GBP 74.1bn
- Enterprise value
- GBP 100.7bn
- Less net debt
- GBP 14.6bn
- Equity value
- GBP 86.1bn
Spread between methods: 57%.
Sensitivity
Value per share (GBP) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 4.72% | 54.99 | 63.16 | 74.99 | 93.69 | 127.75 |
| 5.72% | 40.91 | 45.04 | 50.45 | 57.83 | 68.53 |
| 6.72% | 32.23 | 34.62 | 37.56 | 41.28 | 46.15 |
| 7.72% | 26.36 | 27.85 | 29.63 | 31.76 | 34.40 |
| 8.72% | 22.13 | 23.11 | 24.25 | 25.58 | 27.16 |
Outlined: this model. Green text: above today's price of 18.77. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 3.7% | -10.5% | -14.1pp |
| EBIT margin | 22.6% | 11.0% | -11.6pp |
| Discount rate | 6.7% | 10.2% | +3.5pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.